Long-term Survival Outcomes of Aortic Valve Prostheses: Biological vs. Mechanical in Middle-Aged Patients

By João L. Carapinha

February 17, 2025

Are mechanical aortic valves the overlooked champions in long-term patient survival? A recent article compared the long-term clinical outcomes in patients 50–70 years receiving biological versus mechanical aortic valve prostheses. This research provides valuable insights into the clinical effectiveness of different valve types.

Objectives

The primary objective was to compare long-term survival among patients receiving mechanical or biological aortic valve prostheses. Secondary objectives included assessing trends, early clinical outcomes, the need for repeat valvular intervention, and the effect of valve size and patient-prosthesis mismatch (PPM) on long-term outcomes.

Methods

The study included all consecutive patients 50-70 years who underwent isolated SAVR from 1996 to 2023. The study excluded patients with acute or chronic infective endocarditis, those undergoing emergency or salvage procedures, those with previous cardiac surgery, and recipients of an allograft or homograft.

The local audit committee approved the study, waived individual patient consent, and used prospectively collected data. The researchers divided patients into two groups based on whether they received a biological or mechanical prosthesis. Statistical analysis involved Pearson’s chi-squared test, Wilcoxon rank-sum test, and one-way/multifactor analysis of variance, with IPTW (inverse probability of treatment weighting) applied to balance covariates between the groups. The researchers used Kaplan–Meier plots and log-rank analysis to compare survival curves.

Results

The results indicated no significant differences in cardiopulmonary bypass time, aortic cross-clamp time, and in-hospital mortality. Similarly, return to theatre, neurological events, post-operative need for dialysis, or deep sternal wound infection were not different between the two groups. Notably, patients who received mechanical aortic valve prostheses showed better long-term survival compared to those with biological prostheses (log-rank, P < 0.001). However, there was no significant difference in freedom from repeat valvular intervention between the groups.

The study highlighted the significance of PPM, particularly with smaller-sized valves. Severe PPM was associated with poorer short-term and long-term outcomes. The incidence of severe PPM was higher in this study compared to other reports, such as the PARTNER trials.

Conclusion

This study is limited by its single-institution design, retrospective nature, and lack of randomization, which may introduce various biases. Also, the absence of echocardiographic information and potential residual biases due to unmeasured confounders were noted.

The findings suggest that mechanical aortic valve prostheses may offer superior long-term survival benefits for patients aged 50-70 years. This is particularly true with smaller-sized valves. This challenges the prevailing trend favoring biological valves in this demographic. The authors emphasize the need for careful consideration of the longevity benefits associated with mechanical valves, despite the requirement for long-term anticoagulation.

The study has notable implications for decision-making in SAVR for individuals in the 50-70 age group. It suggests a reconsideration of the choice between biological and mechanical aortic valve prostheses based on long-term survival benefits and the impact of PPM.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.